Janssen Pharmaceutical

FDA approves Janssen’s Invokana for type 2 diabetes

Monday, April 1, 2013 02:15 PM

The FDA has approved Janssen Pharmaceuticals’ Invokana (canagliflozin) for the treatment of adults with type 2 diabetes.

More... »

Janssen, Bayer, Portola form clinical collaboration

Friday, February 8, 2013 11:17 AM

Janssen Pharmaceuticals has signed a clinical collaboration agreement with Portola Pharmaceuticals and Bayer HealthCare to evaluate the safety of PRT4445—an investigational-stage antidote for Factor Xa inhibitors—in healthy volunteers who have been administered the oral anticoagulant Xarelto (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant activity of Xarelto in emergency situations.

More... »

Idenix Pharmaceuticals cancels IDX184 and IDX19368 programs for HCV

Wednesday, February 6, 2013 09:45 AM

Idenix Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the company had previously filed an IND but had not initiated patient dosing.

More... »

FDA grants accelerated approval for Sirturo for multi-drug resistant TB

Wednesday, January 2, 2013 03:13 PM

The FDA has granted accelerated approval to Janssen Therapeutics’ Sirturo (bedaquiline) tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval is based on the surrogate endpoint of time to sputum culture conversion.

More... »

Janssen R&D gains FDA priority review for TB drug

Wednesday, September 5, 2012 11:32 AM

The FDA has granted Janssen Research & Development priority review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

More... »

Janssen buys exclusive access to Evotec's insulin-producing beta cells

Tuesday, July 10, 2012 04:25 PM

Evotec, a drug discovery alliance and development partnership company, has licensed a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells to Janssen Pharmaceuticals.

More... »

Janssen’s Nucynta meets primary endpoint in diabetic peripheral neuropathy study

Monday, May 21, 2012 02:46 PM

Janssen Pharmaceuticals has issued results from an investigational phase III study suggesting Nucynta ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN).

More... »

Index Ventures launches $198 million life sciences fund

Wednesday, March 21, 2012 09:26 AM

Index Ventures, a venture capital firm, has launched its first fund solely dedicated to making investments in the life sciences sector.

More... »

Pepscan achieves milestones from Janssen

Saturday, February 11, 2012 07:53 AM

Pepscan Therapeutics, a Netherlands-based biotechnology firm focusing on protein mimicry technology, has achieved two milestones in the research collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments. 

More... »

Janssen, Pharmacyclics collaborate to develop anti-cancer drug

Friday, December 9, 2011 07:56 AM

Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has executed an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765. A number of phase I and II studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

More... »